Compare Cronos Group Inc (CRON) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Payoneer Global Inc — how do they compare? Cronos Group Inc trades at $2.74 (market cap $1.02B), while Payoneer Global Inc trades at $7.11 (market cap $2.40B). The key difference: Payoneer Global Inc is far larger — about 2.4× Cronos Group Inc's market cap, and Payoneer Global Inc is trading nearer its 52-week high, Cronos Group Inc nearer its low. Which is the better fit depends on your goals.
| CRON | PAYO | |
|---|---|---|
Market Cap | $1.02B | $2.40B |
Sector | Health | Technology |
52-Week High | $3.27 | $7.42 |
52-Week Low | $1.95 | $4.27 |
Enterprise Value | $203.29M | $2.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $2.75, showing no change recently. The stock has a mixed technical outlook with a neutral overall signal but bullish moving averages. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent news highlights strong Q1 2026 revenue growth of 40% and expansion of its Spinach brand portfolio, though the company faces intense cannabis sector competition.
Outlook is cautious with growth potential from international expansion and market share gains, but profitability remains a challenge. Risks include regulatory uncertainty and competitive pressures. Analyst sentiment is mixed with 60% hold ratings. The stock presents a speculative opportunity for investors betting on continued top-line growth and eventual margin improvement.
Payoneer (PAYO) trades at $7.10, flat on the day, with a bullish technical signal driven by moving averages. The company reported Q1 2026 EPS of $0.06, beating expectations, but missed in Q3 and Q4 2025. Revenue grew to $821.16M in 2025, though net income fell to $73.19M. Analysts maintain a 60% buy rating with an $8.20 consensus target. Recent news highlights a $2.75B acquisition by Nuvei and expansion into India, boosting sentiment but raising fairness concerns.
Outlook is mixed: the Nuvei deal offers a near-term exit at $7.40, but growth initiatives like India expansion provide long-term potential. Risks include integration challenges, margin pressure, and shareholder litigation over acquisition terms. The stock's current price near the low target suggests limited upside unless the deal is renegotiated or standalone execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
